The 19th Annual BIO CEO & Investor Conference assembles a select group of established biotech companies, as well as top public and private equity investors and members of the sell-side investment community, to explore the current investment landscape and opportunities in life sciences. In addition to plenary sessions and panel discussions on timely business topics and key therapeutic areas, the conference features presentations by over 175 leading biotechnology and pharmaceutical companies, as well as a number of nonprofit and venture philanthropy organizations.
Presenting companies are hand-selected for the event, and consist of a selection of mid- to large-cap established public companies from around the globe, who typically have a clinical stage program centered around therapeutics, molecular diagnostics, or a platform technology, as well as an upcoming clinical, regulatory, or corporate catalyst.
The typical audience for a company presentation features public and private equity investors, as well as industry analysts, investment bankers and senior biotechnology executives. Public company presentations are 25 minutes in length. Private companies are 13 minutes in length, and are noted as such in the conference program and materials. All Q&A from the audience, should a company want to take questions, are included in those times.
A special track of presentations will once again feature private companies. Presentations in this track will be 13 minutes in length, and will be reserved specifically for established private companies (past Series B round and >$25M raised to date). Please note, registration fees will remain the same; however, a discounted rate has been created for the private company presentation fee. More information can be found on our Registration Page.
Company Presentation Resources
- See the Full List of Presenting Companies from 2016
- Download the Presentation Details Spreadsheet from 2016
- See the list of Webcasts from 2016
- Company Presentations FAQ
For more information about company presentations, please contact Brian Pinkston.